Jun 26 |
Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial
|
Jun 26 |
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
|
Jun 3 |
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
|
May 7 |
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
|
May 7 |
Lyell Immunopharma First Quarter 2024 Earnings: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)
|
May 6 |
Lyell Immunopharma reports Q1 results
|
May 6 |
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
|
Apr 16 |
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
|
Apr 9 |
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
|
Mar 17 |
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an impact on institutional owners after a year of 1.4% returns
|